MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas

Pancreatology

Volumn 13, Issue 6, 2013, Pages 583-588

  Masuda, Atsuhiro ^a   Arisaka, Yoshifumi ^a   Hara, Shigeo ^a   Matsumoto, Ippei ^a   Takenaka, Mamoru ^a   Sakai, Arata ^a   Shiomi, Hideyuki ^a   Matsuki, Nobuyuki ^a   Sugimoto, Maki ^a   Fujita, Tsuyoshi ^a   Hayakumo, Takanobu ^a   Ku, Yonson ^a   Ogino, Shuji ^b,c,d   Azuma, Takeshi ^a   Kutsumia, Hiromu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

High grade dysplasia; Invasive carcinoma; IPMN MUC2 expression; Mixed type

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 6;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DYSPLASIA; FEMALE; HIGH GRADE DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS CYST; PANCREAS DUCT; PANCREAS RESECTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

BD-IPMN; BRANCH DUCT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM; COMPUTED TOMOGRAPHY; CT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; ERCP; EUS; EUS-FNA; HGD; HIGH-GRADE DYSPLASIA; INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM; INVASIVE CARCINOMA; IPMN; LGD; LOW-GRADE DYSPLASIA; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MAGNETIC RESONANCE IMAGING; MAIN DUCT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM; MAIN PANCREATIC DUCT; MCN; MD-IPMN; MIXED-TYPE IPMN; MPD; MRCP; MRI; MUC2 EXPRESSION; MUCINOUS CYSTIC NEOPLASM;

ADENOCARCINOMA, MUCINOUS; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUCIN-2; MUCINS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84892585060     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2013.08.007     Document Type: Article

References (23)

1. Tanaka M, Ferná ndez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183e97.
2. Furukawa T, Klö ppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794e 9.
3. DAngelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004; 239: 400e8.
4. Lü ttges J, Zamboni G, Longnecker D, Klö ppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 2001; 25: 942e8.
5. Mino-Kenudson M, Ferná ndez-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011; 60: 1712e20.
6. Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 2011; 60: 509e16.
7. Crippa S, Ferná ndez-Del Castillo C, Salvia R, Finkelstein D, Bassi C, Domnguez I, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2010; 8: 213e9.
8. Tang RS, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008; 6: 815e9 quiz 719.
9. Osako M, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS, et al. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993; 71: 2191e9.
10. Yonezawa S, Horinouchi M, Osako M, Kubo M, Takao S, Arimura Y, et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int 1999; 49: 45e54.
11. Horinouchi M, Nagata K, Nakamura A, Goto M, Takao S, Sakamoto M, et al. Expression of different glycoforms of membrane mucin(MUC1) and secretory mucin (MUC2, MUC5AC and MUC6) in pancreatic neoplasms. Acta Histochem Cytochem 2003; 36: 443e53.
12. Matsumoto T, Aramaki M, Yada K, Hirano S, Himeno Y, Shibata K, et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2003; 36: 261e5.
13. Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004; 28: 839e48.
14. Nakamura A, Horinouchi M, Goto M, Nagata K, Sakoda K, Takao S, et al. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol 2002; 197: 201e10.
15. Hara T, Ikebe D, Odaka A, Suda K, Nakamura K, Yamamoto H, et al. Preoperative Histological Subtype Classification of Intraductal Papillary Mucinous Neoplasms (IPMN) by Pancreatic Juice Cytology With MUC Stain. Ann Surg 2013.
16. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17e32.
17. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumors. 7th ed. Oxford, UK: Wiley-Blackwell; 2009.
18. Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000; 24: 1372e7.
19. Kobari M, Egawa S, Shibuya K, Shimamura H, Sunamura M, Takada K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999; 134: 1131e6.
20. Doi R, Fujimoto K, Wada M, Imamura M. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002; 132: 80e5.
21. Yonezawa S, Taira M, Osako M, Kubo M, Tanaka S, Sakoda K, et al. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int 1998; 48: 319e22.
22. Hibi Y, Fukushima N, Tsuchida A, Sofuni A, Itoi T, Moriyasu F, et al. Pancreatic juice cytology and subclassification of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2007; 34: 197e204.
23. Maker AV, Katabi N, GonenM, DeMatteo RP, DangelicaMI, FongY, et al.Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 2011; 18: 199e206.